<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="1-part\PMC6718459\results\search\tropicalVirus\results.xml">
  <result pre="Immunization Strategies Be an Alternative and Promising Vaccine Approach Against" exact="Dengue" post="Virus? ValdésIrisLazoLauraHermidaLissetGuillénGerardoGilLázaro*[], Vaccine Department, Center for Genetic Engineering and"/>
  <result pre="is permitted which does not comply with these terms. Abstract" exact="Dengue" post="is one of the most important diseases transmitted by"/>
  <result pre="mucosal surfaces, in case of some pathogens (6, 9, 10)." exact="Dengue" post="is a mosquito-transmitted viral infection of high incidence worldwide"/>
  <result pre="million infections and 20,000 deaths annually around the world (14)." exact="DENV" post="are transmitted mainly by Aedes aegypti mosquitoes, and the"/>
  <result pre="These chimeric viruses only induce neutralizing antibodies against the four" exact="DENV" post="after three doses given 6 month apart (22). Unfortunately,"/>
  <result pre="Infectious Diseases (NIAID). This vaccine combined the molecular attenuation of" exact="DENV" post="by deletions in the 3′ untranslated region and structural"/>
  <result pre="against different viral diseases, such as: HCV, HSV, HIV, and" exact="HPV" post="(8). Complementary prime-boost immunization strategies have also been developed"/>
  <result pre="the experimentation. Complementary Prime-Boost Immunization Strategies For The Development Of" exact="Dengue" post="Vaccines In the specific case of DENV, prime-boost immunization"/>
  <result pre="unfortunately there is no a safe and efficacy vaccine against" exact="DENV" post="neither antiviral drugs for the treatment of infected patients."/>
  <result pre="DIIIC successfully recalled memory B and T cells generated after" exact="DENV" post="infection Monkeys (75) Table 2 Posted clinical trials evaluating"/>
  <result pre="DENV infection Monkeys (75) Table 2 Posted clinical trials evaluating" exact="Dengue" post="vaccine candidates in a prime-boost regime. Vaccine candidate Status"/>
  <result pre="induction of neutralizing antibodies and T-cell specific response to both" exact="DENV" post="serotypes (67). Unfortunately, this study did not evaluate the"/>
  <result pre="conducted to investigate the effect of the pre-existing immunity to" exact="DENV" post="or YFV on the immunogenicity of a tetravalent live-attenuated"/>
  <result pre="investigate the effect of the pre-existing immunity to DENV or" exact="YFV" post="on the immunogenicity of a tetravalent live-attenuated vaccine in"/>
  <result pre="Furthermore, viremia in individuals that were primed with the monovalent" exact="DENV" post="vaccine was lower than those measured in the group"/>
  <result pre="Additionally, the immune response generated by the non-structural protein from" exact="YFV" post="play a role controlling the viremia too. However, the"/>
  <result pre="be discussed below. Tetra DIIIC: A Subunit Vaccine Candidate Against" exact="DENV" post="and Its Potential Use in Complementary Prime-Boost Strategies Experimental"/>
  <result pre="by a Cuban group that developed a vaccine candidate against" exact="DENV" post="based on the DIII of E protein and also"/>
  <result pre="the potentiality of Tetra DIIIC as a vaccine candidate against" exact="DENV" post="and also its usefulness in prime-boost immunization strategies employing"/>
  <result pre="developed neutralizing antibodies and protective immune responses against the four" exact="DENV" post="serotypes. Additionally, the immune response generated by Tetra DIIIC"/>
  <result pre="demonstrating that this formulation induces neutralizing antibodies against the four" exact="DENV" post="serotypes in &amp;gt;90% of those vaccinated in the absence"/>
  <result pre="maturation and duration of the immune response against the four" exact="DENV" post="serotypes. Conclusions Despite the introduction of Dengvaxia®, a vaccine"/>
  <result pre="With this scenario and knowing the complexity associated to a" exact="DENV" post="vaccine due to the immunopathological phenomena that produce the"/>
  <result pre="into account the lessons learned from previous studies conducted with" exact="DENV" post="and other human pathogens, complementary prime-boost immunization strategy must"/>
  <result pre="microorganism and infected cells. Besides, in the specific case of" exact="DENV" post="a good memory B and T-cell responses should be"/>
  <result pre="on the immunogenicity and efficacy role of prime-boost strategies against" exact="DENV" post="will be available. Further studies will be addressed to"/>
  <result pre="a prime-boost immunization regimen could be a potential solution for" exact="DENV" post="vaccine, which is unsolved today. Author Contributions IV, LL,"/>
  <result pre="10.1093/infdis/jiv08225801652 88.ValdésIIzquierdoACobasKThaoPAnhDHDucLHet al.. A heterologous prime-boost strategy for immunization against" exact="Dengue" post="virus combining the Tetra DIIIC subunit vaccine candidate with"/>
 </snippets>
</snippetsTree>
